Morgan Ebert, Executive Editor

Starting antiviral therapy within 48 hours of influenza symptom onset was associated with an 81% lower hospitalization risk in children.

A microbial metabolite, isovalerate, and its precursor leucine restored gut barrier function in malnourished mice, a preclinical study found.

A Rutgers-led study finds teens who follow beauty influencers or watch tutorials use significantly more personal care products, many containing endocrine-disrupting chemicals.

Pediatric psychologist Jeff Temple, PhD, explains how pediatricians can help families establish healthy routines and more intentional screen use.

A meta-analysis of 190 studies and 2.8 million children pinpoints eczema, delayed allergens, and antibiotics as top food allergy risks.

In 38 late preterm/early-term dyads, breast milk composition shifted by week 8 while maternal gut stayed stable, and infant gut Bifidobacterium rose.

New approvals and emerging data are expanding nonsteroidal topical treatment options for several chronic pediatric skin conditions.

Adverse childhood experiences may affect pediatric skin disease risk and outcomes, but researchers say evidence remains limited.

Scholar Rock says apitegromab's SMA BLA stays on track for its September 30, 2026, PDUFA date after dropping one of 2 fill-finish sites.

Executive order seeks to trim routine childhood vaccines, split combination shots, and push parent-doctor decisions—sparking debate as measles surges.

Revised Anaphylm packaging cut pouch-opening time from 17 to 3 seconds, and self-administered PK matched clinician-administered data.

FDA accepted Merck's sBLA extending ENFLONSIA (clesrovimab-cfor) to high-risk children under 2 in their second RSV season.

A look back at the FDA approvals, regulatory decisions, and pipeline updates in the pediatric health care space from July 2026.

A look back at the latest clinical trial updates for the pediatric population during July 2026.

A large prospective US cohort study found no evidence that neonatal medical male circumcision was associated with autism diagnosis or autism traits.

A systematic review found chronic pediatric skin disorders are consistently associated with psychological distress, reduced quality of life, and caregiver burden.

Poison center data show most water bead ingestions are mild, but children younger than 2 years face higher risk for serious outcomes.

Many families with a first-degree history of type 1 diabetes underestimate their risk, highlighting opportunities for pediatricians to discuss screening.

In the OUTMATCH trial, omalizumab achieved higher treatment success than multiallergen oral immunotherapy, largely because of fewer adverse events.

The FDA has approved novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) centanafadine for ADHD in children, adolescents, and adults

FDA approved Tylenol with Naproxen, the first OTC fixed-dose acetaminophen/naproxen sodium tablet, for 12-hour pain relief in patients 12 and older.

A pooled ADORING trial analysis found tapinarof cream improved skin clearance by week 2 across ages 2 through adulthood in atopic dermatitis.

Serial prenatal amnioinfusions improved survival in fetal renal failure, but surviving infants require complex multidisciplinary care after birth.

The SMARTER trial found prenatal and postnatal safe sleep video texting did not significantly improve 4 primary sleep outcomes.

Study finds higher intake of ultra-processed foods in early childhood linked to lower volume of several subcortical brain regions by age 6.

Udenafil lowered ELF scores after 12 months in an exploratory Fontan substudy, but liver stiffness measures did not significantly change.

A 2-million-infant Swedish registry study found intramuscular vitamin K nonreceipt rose over 19 years and nearly tripled the odds of intracranial bleeding by 6 months.

FDA accepted BioMarin's sNDA to convert vosoritide's achondroplasia indication to full approval, with a PDUFA date of February 28, 2027.

FDA sent a letter urging infant formula makers to strengthen supply chain oversight after 2 US botulism outbreaks and a global cereulide contamination event.

Tralokinumab showed expected pharmacokinetics and no new safety findings in 28 children with moderate-to-severe atopic dermatitis.